ARL17A and Parkinson disease: This expression remained reduced in PD patients 36 months (V08) after BL, with a decrease of 32.9% (P = 3.80E–02) for LRRC37A and 41.7% (P = 1.90E–02) for ARL17A compared to controls (Fig. 6a,b).